1. Russo J. Hormonal control of breast development. In: DeGroot LJ, Jameson JL, editors. Endocrinology. Philadelphia, PA: WB Saunders, 2001: 2181-2188.
2. Osborne MP. Breast anatomy and development. In: Harris JR, Osborne CK, Morrow M, Lippman ME, editors. Diseases of the Breast. Philadelphia: Lippincott Williams and Wilkins, 2000: 1-13.
3. Going JJ, Anderson TJ, Battersby S, MacIntyre CC. Proliferative and secretory activity in human breast during natural and artificial menstrual cycles. American Journal of Pathology 1988; 130(1):193-204.
4. Hughes LE, Mansel RE, Webster DJ. Aberrations of normal development and involution (ANDI): a new perspective on pathogenesis and nomenclature of benign breast disorders. Lancet 1987; 2:1316-1319.
5. Love SM, Gelman RS, Silen W. Sounding board. Fibrocystic "disease" of the breast--a nondisease? New England Journal of Medicine 1982; 307(16):1010-1014.
6. Houssami N, Cheung MN, Dixon JM. Fibroadenoma of the breast. Medical Journal of Australia 2001; 174(4):185-188.
7. Goehring C, Morabia A. Epidemiology of benign breast disease, with special attention to histologic types. Epidemiologic Reviews 1997; 19(2):310-327.
8. Dent DM, Wilkie W, Hacking ER. Benign breast disease: clinical classification and disease distribution. British Journal of clinical Practice 42 ( supplement 56), 69. 1988.
Ref Type: Journal (Full)
9. Costantini L, Bucchi L, Dogliotti L et al. Cohort study of women with aspirated gross cysts of the breast-an update. In: Mansel RE, editor. Recent Developments in the Study of Benign Breast Disease. London: Parthenon Press, 1993: 227-239.
10. Lee S, Mohsin SK, Mao S, Hilsenbeck SG, Medina D, Allred DC. Hormones, receptors, and growth in hyperplastic enlarged lobular units: early potential precursors of breast cancer. Breast Cancer Research 2006; 8(1):R6.
11. Wood LD, Parsons DW, Jones S et al. The genomic landscapes of human breast and colorectal cancers.[see comment]. Science 2007; 318(5853):1108-1113.
12. Harvey JA, Santen RJ, Petroni GR et al. Histologic changes in the breast with menopausal hormone therapy use: correlation with breast density, estrogen receptor, progesterone receptor, and proliferation indices. Menopause 2008; 15(1):67-73.
13. Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ. Mammographic densities and breast cancer risk. Cancer Epidemiology, Biomarkers & Prevention 1998; 7(12):1133-1144.
14. Rohan TE, Miller AB. Hormone replacement therapy and risk of benign proliferative epithelial disorders of the breast. European Journal of Cancer Prevention 1999; 8(2):123-130.
15. Rohan TE, Negassa A, Chlebowski RT et al. Estrogen plus progestin and risk of benign proliferative breast disease. Cancer Epidemiology, Biomarkers & Prevention 2008; 17(9):2337-2343.
16. Tan-Chiu E, Wang J, Costantino JP et al. Effects of tamoxifen on benign breast disease in women at high risk for breast cancer. Journal of the National Cancer Institute 2003; 95(4):302-307.
17. Allred DC, Mohsin SK. Biological features of human pre-malignant breast disease. In: Harris JR, Osborne CK, Morrow M, Lippman ME, editors. Diseases of the Breast. Philadelphia: Lippincott Williams and Wilkins, 2000: 355-366.
18. O'Connell P, Pekkel V, Fuqua SA, Osborne CK, Clark GM, Allred DC. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. Journal of the National Cancer Institute 1998; 90(9):697-703.
19. Hoogerbrugge N, Bult P, Widt-Levert LM et al. High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. Journal of Clinical Oncology 2003; 21(1):41-45.
20. Lundin C, Mertens F. Cytogenetics of benign breast lesions. Breast Cancer Research & Treatment 1998; 51(1):1-15.
21. Is 'fibrocystic disease' of the breast precancerous? Archives of Pathology & Laboratory Medicine 1986; 110(3):171-173.
22. Shaaban AM, Sloane JP, West CR et al. Histopathologic types of benign breast lesions and the risk of breast cancer: case-control study. American Journal of Surgical Pathology 2002; 26(4):421-430.
23. Khan SA, Apkarian AV. The characteristics of cyclical and non-cyclical mastalgia: a prospective study using a modified McGill Pain Questionnaire. Breast Cancer Research & Treatment 2002; 75(2):147-157.
24. Kessel B. Premenstrual syndrome. Advances in diagnosis and treatment. Obstetrics & Gynecology Clinics of North America 2000; 27(3):625-639.
25. Goodwin PJ, Neelam M, Boyd NF. Cyclical mastopathy: a critical review of therapy. British Journal of Surgery 1988; 75(9):837-844.
26. Goodwin PJ, Miller A, Del Giudice ME, Ritchie K. Breast health and associated premenstrual symptoms in women with severe cyclic mastopathy. American Journal of Obstetrics & Gynecology 1997; 176(5):998-1005.
27. Ader DN, Shriver CD. Cyclical mastalgia: prevalence and impact in an outpatient breast clinic sample. Journal of the American College of Surgeons 1997; 185(5):466-470.
28. Ader DN, South-Paul J, Adera T, Deuster PA. Cyclical mastalgia: prevalence and associated health and behavioral factors. Journal of Psychosomatic Obstetrics & Gynecology 2001; 22(2):71-76.
29. Berg JC, Visscher DW, Vierkant RA et al. Breast cancer risk in women with radial scars in benign breast biopsies. Breast Cancer Research & Treatment 2008; 108(2):167-174.
30. Seltzer MH, Perloff LJ, Kelley RI, Fitts WT, Jr. The significance of age in patients with nipple discharge. Surgery, Gynecology & Obstetrics 1970; 131(3):519-522.
30A. Florio MF, Manganaro T, Pollicino A, Scarfo P, Micali B. Surgical approach to nipple discharge: a ten year experience. Journal of Surgical Oncology 71:2235-238, 1999
31. Smith GE, Burrows P. Ultrasound diagnosis of fibroadenoma - is biopsy always necessary?[see comment]. Clinical Radiology 516; 63(5):511-515.
32. Shetty MK, Shah YP, Sharman RS. Prospective evaluation of the value of combined mammographic and sonographic assessment in patients with palpable abnormalities of the breast. Journal of Ultrasound in Medicine 2003; 22(3):263-268.
33. Moy L, Slanetz PJ, Moore R et al. Specificity of mammography and US in the evaluation of a palpable abnormality: retrospective review. Radiology 2002; 225(1):176-181.
34. Soo MS, Rosen EL, Baker JA, Vo TT, Boyd BA. Negative predictive value of sonography with mammography in patients with palpable breast lesions. AJR American Journal of Roentgenology 2001; 177(5):1167-1170.
35. Flobbe K, Bosch AM, Kessels AG et al. The additional diagnostic value of ultrasonography in the diagnosis of breast cancer. Archives of Internal Medicine 2003; 163(10):1194-1199.
36. Venta LA. Image guided biopsy of non-palpable breast lesions. Harris JR LM, Morrow M OCe, editors. Diseases of the Breast second edition. 149-164. 2000. Philadelphia, Lippincott Williams and Wilkins.
Ref Type: Generic
37. Smith RA. The evolving role of MRI in the detection and evaluation of breast cancer.[comment]. New England Journal of Medicine 2007; 356(13):1362-1364.
38. Ambrogetti D, Berni D, Catarzi S, Ciatto S. The role of ductal galactography in the differential diagnosis of breast carcinoma. Radiologia Medica 1996; 91(3):198-201.
39. Morrow M, Bland KI, Foster R. Breast cancer surgical practice guidelines. Society of Surgical Oncology practice guidelines. Oncology (Huntington) 1997; 11(6):877-881.
40. Fentiman IS, Caleffi M, Brame K, Chaudary MA, Hayward JL. Double-blind controlled trial of tamoxifen therapy for mastalgia. Lancet 1986; 1(8476):287-288.
41. Messinis IE, Lolis D. Treatment of premenstrual mastalgia with tamoxifen. Acta Obstetricia et Gynecologica Scandinavica 1988; 67(4):307-309.
42. O'Brien PM, Abukhalil IE. Randomized controlled trial of the management of premenstrual syndrome and premenstrual mastalgia using luteal phase-only danazol. American Journal of Obstetrics & Gynecology 1999; 180(1):1-23.
43. Millet AV, Dirbas FM. Clinical management of breast pain: a review. Obstetrical & Gynecological Survey 2002; 57(7):451-461.
44. Pashby NL, Mansel RE, Hughes LE, Hanslip JI, Preece P. A clinical trial of evening primrose oil in mastalgi. British Journal of Surgery 1981; 68:801.
45. Preece PE, Hanslip JI, Gilbert L. Evening primrose oil ( Efamol) for mastalgia. In: Horrobin DF, editor. Clinical uses of essential fatty acid. Montreal: Eden, 1982: 147-154.
46. Blommers J, de Lange-De Klerk ES, Kuik DJ, Bezemer PD, Meijer S. Evening primrose oil and fish oil for severe chronic astalgia: a randomized, double-blind, controlled trial. American Journal of Obstetrics & Gynecology 2002; 187(5):1389-1394.
47. Hamed H, Caleffi M, Chaudary MA, Fentiman IS. LHRH analogue for treatment of recurrent and refractory mastalgia. Annals of the Royal College of Surgeons of England 1990; 72(4):221-224.
48. Mansel RE, Goyal A, Preece P et al. European randomized, multicenter study of goserelin (Zoladex) in the management of mastalgia. American Journal of Obstetrics & Gynecology 2004; 191(6):1942-1949.
49. Hartmann LC, Sellers TA, Frost MH et al. Benign breast disease and the risk of breast cancer.[see comment]. New England Journal of Medicine 2005; 353(3):229-237.
50. Degnim AC, Visscher DW, Berman HK et al. Stratification of breast cancer risk in women with atypia: a Mayo cohort study.[see comment]. Journal of Clinical Oncology 2007; 25(19):2671-2677.
51. Stark A, Hulka BS, Joens S et al. HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. Journal of Clinical Oncology 2000; 18(2):267-274.
52. Garcia-Tunon I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M. Role of tumor necrosis factor-alpha and its receptors in human benign breast lesions and tumors (in situ and infiltrative). Cancer Science 2006; 97(10):1044-1049.
53. Santen RJ, Boyd NF, Chlebowski RT et al. Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. [Review] [95 refs]. Endocrine-Related Cancer 2007; 14(2):169-187.
54. Boyd NF, Jensen HM, Cooke G, Han HL, Lockwood GA, Miller AB. Mammographic densities and the prevalence and incidence of histological types of benign breast disease. Reference Pathologists of the Canadian National Breast Screening Study. European Journal of Cancer Prevention 2000; 9(1):15-24.
55. Byrne C, Schairer C, Brinton LA et al. Effects of mammographic density and benign breast disease on breast cancer risk (United States). Cancer Causes & Control 2001; 12(2):103-110.
56. Key T, Appleby P, Barnes I, Reeves G, Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. Journal of the National Cancer Institute 2002; 94(8):606-616.
57. Hulka BS, Moorman PG. Breast cancer: hormones and other risk factors. Maturitas 1928; 38(1):103-113.
58. Chlebowski RT, Hendrix SL, Langer RD et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial.[see comment]. JAMA 2003; 289(24):3243-3253.
59. Prentice RL, Manson JE, Langer RD et al. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause.[see comment]. American Journal of Epidemiology 2009; 170(1):12-23.
60. Fournier A, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F. Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?[see comment]. Journal of Clinical Oncology 2009; 27(31):5138-5143.
61. Gail MH, Brinton LA, Byar DP et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. Journal of the National Cancer Institute 1989; 81(24):1879-1886.
62. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors.[see comment][erratum appears in Stat Med. 2005 Jan 15;24(1):156]. Statistics in Medicine 2004; 23(7):1111-1130.
63. Kuller LH, Cauley JA, Lucas L, Cummings S, Browner WS. Sex steroid hormones, bone mineral density, and risk of breast cancer. Environmental Health Perspectives 1997; 105:Suppl-9.
64. Chlebowski RT, Collyar DE, Somerfield MR, Pfister DG. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. Journal of Clinical Oncology 1999; 17(6):1939-1955.
65. Gail MH, Costantino JP, Bryant J et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. Journal of the National Cancer Institute 1999; 91(21):1829-1846.
66. Levine M, Moutquin JM, Walton R, Feightner J, Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. CMAJ Canadian Medical Association Journal 2001; 164(12):1681-1690.
67. Chlebowski RT, Col N, Winer EP et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. Journal of Clinical Oncology 2002; 20(15):3328-3343.
68. Cuzick J, Powles T, Veronesi U et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003; 361(9354):296-300.
69. Vogel VG. The NSABP Study of Tamoxifen and Raloxifene (STAR) trial. [Review] [35 refs]. Expert Review of Anticancer Therapy 2009; 9(1):51-60.